Conference Coverage
Should BTK Inhibitors be Utilized as Frontline Therapy for Mantle Cell Lymphoma?
06/29/2025
Tycel Phillips, MD, City of Hope, Los Angeles, California, participated in a debate at the 2025 Great Debates in Hematologic Malignancies meeting in New York, New York, in which he argued in favor of utilizing BTK inhibitors to improve overall survival among patients with previously untreated mantle cell lymphoma (MCL), especially those with high-risk features.
Source:
Phillips T. Debate- When Should BTK Inhibitors Be Used to Treat Mantle Cell Lymphoma? Upfront vs Second-Line. Presented at the Great Debates in Hematologic Malignancies meeting. June 28-29, New York, New York.
